CELEX: 62019TA0187
Language: en
Date: 2020-09-09 00:00:00
Title: Case T-187/19: Judgment of the General Court of 9 September 2020 — Glaxo Group Ltd v EUIPO (Shade of the colour purple) (EU trade mark — Application for an EU trade mark consisting of a shade of the colour purple — Absolute ground for refusal — Lack of distinctive character — Article 7(1)(b) of Regulation (EU) 2017/1001 — Lack of distinctive character acquired through use — Article 7(3) of Regulation 2017/1001)

9.11.2020   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 378/30
            
         
      Judgment of the General Court of 9 September 2020 — Glaxo Group Ltd v EUIPO (Shade of the colour purple)
      (Case T-187/19) (1)
      
      (EU trade mark - Application for an EU trade mark consisting of a shade of the colour purple - Absolute ground for refusal - Lack of distinctive character - Article 7(1)(b) of Regulation (EU) 2017/1001 - Lack of distinctive character acquired through use - Article 7(3) of Regulation 2017/1001)
      (2020/C 378/36)
      Language of the case: English
      
         Parties
      
      
         Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: S. Malynicz, QC, S. Baran, Barrister, and R. Jacob, Solicitor)
      
         Defendant: European Union Intellectual Property Office (represented by: S. Hanne and H. O’Neill, acting as Agents)
      
         Re:
      
      Action brought against the decision of the First Board of Appeal of EUIPO of 15 January 2019 (Case R 1870/2017-1), concerning an application for registration of a sign consisting of a shade of the colour purple as an EU trade mark:
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Glaxo Group Ltd to pay the costs.
               
            
         (1)  OJ C 172, 20.5.2019.